A detailed history of Quent Capital, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Quent Capital, LLC holds 61 shares of BPMC stock, worth $5,770. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61
Previous 61 -0.0%
Holding current value
$5,770
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 08, 2024

BUY
$85.18 - $108.78 $170 - $217
2 Added 3.39%
61 $6,000
Q3 2023

Jun 14, 2024

BUY
$46.9 - $66.0 $844 - $1,188
18 Added 43.9%
59 $2,000
Q3 2023

Oct 10, 2023

BUY
$46.9 - $66.0 $844 - $1,188
18 Added 43.9%
59 $2,000
Q2 2023

Jun 14, 2024

BUY
$42.2 - $66.37 $464 - $730
11 Added 36.67%
41 $2,000
Q2 2023

Jul 10, 2023

BUY
$42.2 - $66.37 $464 - $730
11 Added 36.67%
41 $2,000
Q1 2023

Jun 14, 2024

SELL
$37.97 - $50.0 $1,101 - $1,450
-29 Reduced 49.15%
30 $1,000
Q4 2022

Jan 19, 2023

BUY
$41.06 - $66.48 $1,231 - $1,994
30 New
30 $0

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.65B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Quent Capital, LLC Portfolio

Follow Quent Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quent Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quent Capital, LLC with notifications on news.